Crinetics Pharmaceuticals Inc [CRNX] stock prices are up 4.15% to $40.40 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRNX shares have gain 5.70% over the last week, with a monthly amount drifted -21.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies upgraded its rating to Buy on January 22, 2025, and kept the price target unchanged to $55. On March 06, 2024, Citigroup initiated with a Buy rating and assigned a price target of $68 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $50 on January 16, 2024. Jefferies initiated its recommendation with a Hold and recommended $35 as its price target on December 21, 2023.
The stock price of Crinetics Pharmaceuticals Inc [CRNX] has been fluctuating between $35.51 and $62.53 over the past year. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $40.40 at the most recent close of the market. An investor can expect a potential return of 70.79% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at -0.43% with Operating Profit Margin at -295.87%, Pretax Profit Margin comes in at -267.48%, and Net Profit Margin reading is -267.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.36 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.07 points at the first support level, and at 37.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.17, and for the 2nd resistance point, it is at 41.94.
Ratios To Look Out For
It’s worth pointing out that Crinetics Pharmaceuticals Inc [NASDAQ:CRNX]’s Current Ratio is 16.38. Further, the Quick Ratio stands at 16.38, while the Cash Ratio is 5.92.
Transactions by insiders
Recent insider trading involved DANA J PIZZUTI, Officer, that happened on Feb 03 ’25 when 5000.0 shares were purchased. Chief Med and Dev Officer, Pizzuti Dana completed a deal on Jan 03 ’25 to sell 15000.0 shares. Meanwhile, Officer DANA J PIZZUTI bought 15000.0 shares on Jan 03 ’25.
